Boston, MA – According to filings with the U.S. Securities and Exchange Commission, AZTherapies is raising $7,500,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Elmaleh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AZTherapies AZTherapies, Inc. is a privately-held drug targeting company founded in 2011 and headquartered in Boston, MA.  We are innovating the discovery, development and commercialization of novel Alzheimer’s disease therapeutics which will fundamentally improve patient treatment, quality of life and disease management.  Preventing Alzheimer’s disease  progression remains a critical unmet need for millions of persons in the US and worldwide. Our advanced knowledge of Alzheimer’s disease biology, combined with our proprietary scientific discovery, clinical and biomarker imaging expertise, provide AZTherapies with unique prospects to develop novel therapies to impact Alzheimer’s disease progression.

To learn more about AZTherapies, visit http://aztherapies.com/

Contact:
David Elmaleh, Chief Executive Officer
617-318-3411
david.elmaleh@aztherapies.com
https://www.linkedin.com/in/david-elmaleh-787ab1150/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved